His primary areas of investigation include Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. His Endocrinology research extends to the thematically linked field of Internal medicine. His Breast cancer research includes elements of Randomized controlled trial, Surgery and Pathology.
His Oncology research integrates issues from Trastuzumab, Metastatic breast cancer, Docetaxel, Bevacizumab and Adjuvant therapy. His Cancer study combines topics from a wide range of disciplines, such as Disease, Immunology and Exome. His study focuses on the intersection of Chemotherapy and fields such as Clinical endpoint with connections in the field of Clodronic acid and Placebo.
His primary scientific interests are in Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Cancer. His research links Surgery with Internal medicine. His Oncology research incorporates themes from Bevacizumab, Triple-negative breast cancer and Taxane.
His Breast cancer research is multidisciplinary, incorporating elements of Cancer research, Clinical trial, Pathology, Gynecology and Adjuvant therapy. He focuses mostly in the field of Metastatic breast cancer, narrowing it down to matters related to Capecitabine and, in some cases, Docetaxel. As part of his studies on Cancer, Adam Brufsky often connects relevant areas like Cohort.
Adam Brufsky mainly focuses on Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Cancer. His study in Oncology is interdisciplinary in nature, drawing from both Letrozole, Clinical endpoint, Triple-negative breast cancer and Phases of clinical research. Neoadjuvant therapy is closely connected to Adjuvant in his research, which is encompassed under the umbrella topic of Breast cancer.
His Metastatic breast cancer research is multidisciplinary, relying on both Cancer research, Fulvestrant, Tyrosine-kinase inhibitor and Hazard ratio. Adam Brufsky regularly links together related areas like Overall survival in his Cancer studies. The various areas that Adam Brufsky examines in his Chemotherapy study include Taxane, Disease and Anthracycline.
His scientific interests lie mostly in Internal medicine, Virology, Breast cancer, Oncology and Metastatic breast cancer. He combines subjects such as Immunology, Pathogenesis and Virulence with his study of Virology. His Breast cancer research includes themes of Regimen and Chemotherapy regimen.
His research integrates issues of Previously treated, Sacituzumab govitecan, Triple-negative breast cancer and Prostate cancer in his study of Oncology. His study with Metastatic breast cancer involves better knowledge in Cancer. His work on Fulvestrant, Palbociclib and Letrozole as part of general Cancer research is frequently linked to Clinical Practice, thereby connecting diverse disciplines of science.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt;Robert S. Fulton;Michael D. McLellan;Heather Schmidt.
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky.
Journal of Clinical Oncology (2011)
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard.
The New England Journal of Medicine (2015)
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.
Edward Giovannucci;Meir J. Stampfer;Krishna Krithivas;Myles Brown.
Proceedings of the National Academy of Sciences of the United States of America (1997)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard.
The New England Journal of Medicine (2018)
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Nancy U Lin;Véronique Diéras;Devchand Paul;Dominique Lossignol.
Clinical Cancer Research (2009)
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Stephen Chia;William Gradishar;Louis Mauriac;Jose Bines.
Journal of Clinical Oncology (2008)
Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer
Adam Brufsky;W. Graydon Harker;J. Thaddeus Beck;Robert Carroll.
Journal of Clinical Oncology (2007)
Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Edward H. Romond;Jong Hyeon Jeong;Priya Rastogi;Sandra M. Swain.
Journal of Clinical Oncology (2012)
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Harry D. Bear;Gong Tang;Priya Rastogi;Charles E. Geyer.
The New England Journal of Medicine (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: